Cargando…

The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome

OBJECTIVES: Beta-lactam antibiotics are often subject to therapeutic drug monitoring, but breakpoints of target attainment are mostly based on expert opinions. Studies that show a correlation between target attainment and infection resolution are missing. This analysis investigated whether there is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scharf, Christina, Liebchen, Uwe, Paal, Michael, Taubert, Max, Vogeser, Michael, Irlbeck, Michael, Zoller, Michael, Schroeder, Ines
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686672/ https://www.ncbi.nlm.nih.gov/pubmed/33292582 http://dx.doi.org/10.1186/s40560-020-00504-w

Ejemplares similares

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis
por: Scharf, Christina, et al.
Publicado: (2021)

Can the cytokine adsorber CytoSorb(®) help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis
por: Scharf, Christina, et al.
Publicado: (2021)

Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study
por: Scharf, Christina, et al.
Publicado: (2021)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
por: Kallee, Simon, et al.
Publicado: (2022)

Does the cytokine adsorber CytoSorb(®) reduce vancomycin exposure in critically ill patients with sepsis or septic shock? a prospective observational study
por: Scharf, Christina, et al.
Publicado: (2022)

CytoSorb® Hemoadsorption as a Promising Tool to Handle COVID-19-Induced Cytokine Storm
por: Acevedo, Alice-Christin, et al.
Publicado: (2021)

Digestive enzymes of fungal origin as a relevant cause of false positive Aspergillus antigen testing in intensive care unit patients
por: Schroeder, Ines, et al.
Publicado: (2020)

The Role of Non-Enzymatic Degradation of Meropenem—Insights from the Bottle to the Body
por: Liebchen, Uwe, et al.
Publicado: (2021)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

The effect of cytosorb® application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis
por: Gräfe, Caroline, et al.
Publicado: (2023)

The cytokine adsorber Cytosorb® does not reduce ammonia concentrations in critically ill patients with liver failure
por: Liebchen, Uwe, et al.
Publicado: (2023)

Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC–MS/MS method in human serum
por: Habler, Katharina, et al.
Publicado: (2021)

Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study
por: Greimel, Antonia, et al.
Publicado: (2023)

Was ist neu … in der Behandlung von invasiven Mykosen. COVID-19-assoziierte pulmonale Aspergillose
por: Scharf, Christina, et al.
Publicado: (2021)

Nichtinvasive respiratorische Unterstützung und invasive Beatmung bei COVID‑19: Wo stehen wir heute?
por: Schroeder, Ines, et al.
Publicado: (2022)

Therapeutic drug monitoring-guided high dose meropenem therapy of a multidrug resistant Acinetobacter baumannii - A case report
por: Liebchen, U., et al.
Publicado: (2019)

No clinically relevant removal of meropenem by cytokine adsorber CytoSorb(®) in critically ill patients with sepsis or septic shock
por: Liebchen, Uwe, et al.
Publicado: (2021)

Comparison of Cerebrospinal Fluid Collection Through the Proximal and Distal Port Below the Overflow System from an External Ventricular Drain
por: Kinast, Christina Barbara, et al.
Publicado: (2022)

Estimation of inter-laboratory reference change values from external quality assessment data
por: Paal, Michael, et al.
Publicado: (2021)

Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation study
por: Liebchen, Uwe, et al.
Publicado: (2021)

Charakteristika und Outcome von 70 beatmeten COVID-19-Patienten: Bilanz nach der ersten Welle an einem universitären Zentrum
por: Schroeder, Ines, et al.
Publicado: (2020)

Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics
por: Zmarlicka, Monika T, et al.
Publicado: (2015)

1186. Beta is Better: Impact of a Multifaceted Stewardship Initiative on the Sequential Timing of Beta-Lactam Administration
por: Deri, Connor R, et al.
Publicado: (2023)

Beta lactam hypersensitivities
por: Azoury, Marie Eliane*, et al.
Publicado: (2014)

Beta-lactam hypersensitivity: not always what it seems
por: Andrade, Djanira, et al.
Publicado: (2015)

Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
por: Schatz, Lea Marie, et al.
Publicado: (2023)

New boronate drugs and evolving NDM-mediated beta-lactam resistance
por: Lomovskaya, Olga, et al.
Publicado: (2023)

1805. Safety Outcomes Following Beta-Lactam use in Patients with a Documented Beta-Lactam Allergy
por: Rampersad, Daniel, et al.
Publicado: (2022)

Genetic associations in beta-lactam allergy
por: Gueant, Jean-Louis, et al.
Publicado: (2014)

Endopeptidase-Mediated Beta Lactam Tolerance
por: Dörr, Tobias, et al.
Publicado: (2015)

Profile of Enterobacteria Resistant to Beta-Lactams
por: Santos, Andressa Liberal, et al.
Publicado: (2020)

Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
por: Dhaese, Sofie A. M., et al.
Publicado: (2022)

The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition
por: Turner, Jonathan, et al.
Publicado: (2022)

${\beta*}$-reach in 2017
por: Bruce, R, et al.
Publicado: (2017)

Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study
por: Zander, Johannes, et al.
Publicado: (2016)

Low dose oral beta-lactamase protects the gut microbiome from oral beta-lactam-mediated damage in dogs
por: Connelly, Sheila, et al.
Publicado: (2019)

Higher in status, (Even) better-than-average
por: Varnum, Michael E. W.
Publicado: (2015)

THE BETA-LACTAM ANTIBIOTICS: Penicillins and Cephalosporins in Perspective
Publicado: (1980)

Use of beta-lactams antibiotics in ICU patients
por: Damas, M-P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_r2098248c3h30mma6n2l2as7s7